Here's Why You Should Retain Insulet (PODD) Stock for Now

Insulet Corporation (PODD) is poised to gain in the coming quarters owing to the strength of its revolutionary offering, the Omnipod 5 Automated Insulin Delivery (“AID”) system. The flourishing diabetes market raises optimism for the company’s operations. A strong solvent balance sheet is highly encouraging.  Meanwhile, elevated costs and the impact of macroeconomic pressures may adversely affect Insulet’s results of operations.In the past year, this Zacks Rank #3 (Hold) stock has decreased 35.6% against th ...